JACC: HEART FAILURE
ª 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
VOL. 3, NO. 6, 2015
ISSN 2213-1779/$36.00
PUBLISHED BY ELSEVIER INC.
CORRECTION
Kiernan MS, Gregory D, Sarnak MJ, Rossignol P, Massaro J, Kociol R, Zannad F, Konstam MA.
Early and Late Effects of High- Versus Low-Dose Angiotensin
Receptor Blockade on Renal Function and Outcomes in Patients
With Chronic Heart Failure
J Am Coll Cardiol HF 2015;3:214–23
The first 2 sentences of the Results section of the Abstract contained some value errors. The corrected sentences are below.
Compared with 50 mg, 150 mg losartan led to a greater reduction in eGFR across time (mean difference:
3.76 ml/min/1.73 m 2; p < 0.0001). This difference was driven by early changes, and differences in eGFR
after 4 months were not significant (mean difference: 0.42 ml/min/1.73 m 2; p ¼ 0.15).
In the Impact of Losartan Dose on Renal Function section in the Results, the first 2 sentences contained value
errors. The corrected sentences are below:
eGFR levels were significantly lower at each time point in the 150-mg group compared with the 50-mg group.
The mean difference in eGFR between groups across time was 3.76 ml/min/1.73 m 2 (95% confidence
interval [CI]: 4.07 to -3.46; p < 0.0001) (Figure 1A).
The second to last sentence in the 2nd paragraph of the Discussion contained value errors. The corrected
sentence is below:
Interestingly, the treatment effect seen in the Val-HeFT (Valsartan in Heart Failure Trial) analysis between
the placebo and valsartan groups was similar to the treatment effect seen between the high-dose and
low-dose groups in the present HEAAL analysis (3.76 ml/min/1.73 m 2).
The figure and legend have printed incorrectly. The corrected figure and legend are below.
The online version has been corrected to reflect these changes.
JACC: HEART FAILURE VOL. 3, NO. 6, 2015
Correction
JUNE 2015:510–1
F I G U R E 1 Mixed Model Estimates of the Effect of Losartan Dose on eGFR Over Time
(A) Parameter estimates from repeated measures for mean changes from baseline estimated glomerular filtration rate (eGFR) over time. The red line represents patients
taking losartan 50 mg daily, whereas the blue line represents patients taking 150 mg. The mean effect of high-dose losartan on eGFR over time compared with low-dose
losartan was 3.76 ml/min/1.73 m2/month (95% confidence interval [CI]: 4.07 to 3.46; p < 0.0001). The error bars span 2 standard errors. (B) Landmark analysis for
the mixed model estimate of effect of losartan dose on eGFR over time with baseline at month 4. Parameter estimates from repeated measures for mean change in eGFR
from month 4 through follow-up between treatment groups. Changes in eGFR that occurred before month 4 are ignored. The red line represents patients taking losartan
50 mg daily, whereas the blue line represents those taking 150 mg. The mean effect of high-dose losartan on eGFR over time compared with low-dose losartan was
0.42 ml/min/1.73 m2/month (95% CI: 0.14 to 0.98; p ¼ 0.15).
The authors apologize for this error.
http://dx.doi.org/10.1016/j.jchf.2015.03.002
511